INmune Bio's TNF Inhibitor Fails Phase II Primary Endpoint in Alzheimer's Trial

INmune Bio's XPro (pegipanermin), a brain-penetrant tumour necrosis factor (TNF) inhibitor, missed the primary endpoint in the Phase II MINDFuL trial (n=200) for early Alzheimer's disease (AD), showing no significant difference in Early Mild AD Cognitive Composite (EMACC) scores versus placebo at 24 weeks. However, prespecified subgroup analyses revealed potential benefits in amyloid-positive patients with ≥2 inflammatory biomarkers, demonstrating favourable effects on cognition (effect size 0.27), neuropsychiatric symptoms (−0.24) and blood pTau217 levels (−0.20).

XPro exhibited a safety profile consistent with prior studies, with injection-site reactions (80%) as the most common adverse event. INmune Bio plans to discuss a pivotal trial pathway with regulatory authorities in its US homeland in Q4 2025, citing consistent signals across clinical and biomarker endpoints. Full results will be presented at the Alzheimer's Association International Conference (AAIC) 2025.

Daily News
Laekna's Afuresertib Succeeds in Phase III Trial for HR+/HER2- Breast Cancer
2026-04-16
MSD, Daiichi Sankyo Submit First BLA for B7-H3 ADC for SCLC
2026-04-16
Bio-Thera to Transfer CVD Drug to Lepu Pharma for RMB 450m
2026-04-15
J&J Reports 9.9% Q1'26 Revenue Growth, Raises Full-Year Guidance
2026-04-15
Regeneron, Telix Shake on Next-Gen Radiopharmaceuticals
2026-04-14
Latest Report
Global Drug Progress Report during January 2026
Details